MannKind Corporation (MNKD)

CIK 0000899460 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-05) · 99.1
Q1-2026 8-K (2026-05-06) · 99.1
Latest FY-2025 8-K (2026-02-26) · 99.1
Q3-2025 8-K (2025-11-05) · 99.1
Q2-2025 8-K (2025-08-06) · 99.1
Q1-2025 8-K (2025-05-08) · 99.1
FY-2024 8-K (2025-02-26) · 99.1
Q3-2024 8-K (2024-11-07) · 99.1
Q2-2024 8-K (2024-08-07) · 99.1
Q1-2024 8-K (2024-05-08) · 99.1
FY-2023 8-K (2024-02-27) · 99.1
Q3-2023 8-K (2023-11-07) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive (loss) Income
—
Condensed Consolidated Statements of Comprehensive Income
—
Consolidated Statements of Comprehensive Income (loss)
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Comprehensive Loss
—
Consolidated Statements of Stockholders' Deficit
Consolidated Statements of Cash Flows
Notes
Accounts Receivable
Accrued Expenses and Other Current Liabilities
Acquisition
Borrowings
Business Combinations
Collaborations, Licensing and Other Arrangements
Commitments and Contingencies
Common and Preferred Stock
Cybersecurity Risk Management, Strategy, and Governance
—
Description of Business
—
Description of Business and Significant Accounting Policies
—
Earnings Per Common Share
Earnings Per Common Share ("eps")
Employee Benefit Plans
—
Fair Value of Financial Instruments
Goodwill and Other Intangible Assets
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Inventories
Investments
Pay Vs Performance Disclosure
Property and Equipment
Pulmatrix Transaction
Stock Award Plans
—
Stock-based Compensation Expense
—
Subsequent Event
—
Summary of Significant Accounting Policies
—